Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 10/20 | 0.35 |
| ▸ | CDK1 | P06493 | 10/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 10/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074583 | 0.75 | — | — | |
| SCHEMBL2334434 | 0.71 | — | — | |
| SCHEMBL4569212 | 0.64 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4569220 | 0.63 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24995564 | 0.62 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25917562 | 0.62 | CCNB2 (0.42) | CCNB2CDK1CCNB1CCNB3CYP1A2 | |
| SCHEMBL14667015 | 0.60 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24174573 | 0.60 | NOS3 (0.35) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25030573 | 0.59 | — | — | |
| SCHEMBL25803197 | 0.58 | PI4KA (0.30) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | GRM4 1741/4885CCNB2 519/4885CDK1 526/4885 |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | GRM4 1235/4885CCNB2 1001/4885CDK1 1824/4885 |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | GRM4 1074/4885CCNB2 107/4885CDK1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.